P2X7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study-Reference-Cited by-同舟云学术

P2X7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study

Published:2024-04-01 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Lehto Jussi¹^ORCID,Aarnio Richard¹,Tuisku Jouni¹,Sucksdorff Marcus¹,Koivumäki Esa Mikko¹,Nylund Marjo¹,Helin Semi¹,Rajander Johan²,Danon Jonathan³,Gilchrist Jayson³,Kassiou Michael³,Oikonen Vesa¹,Airas Laura¹

Affiliation:

1. Turku PET Centre: Turun PET keskus

2. Åbo Akademi University: Abo Akademi

3. The University of Sydney School of Chemistry

Abstract

Background PET imaging of activated microglia has improved our understanding of the pathology behind disability progression in MS, and pro-inflammatory microglia at ‘smoldering’ lesion rims have been implicated as drivers of disability progression. The P2X₇R is upregulated in the cellular membranes of activated microglia. A single-tissue dual-input model was applied to quantify P2X₇R binding in the normal appearing white matter, perilesional areas and thalamus among progressive MS patients, healthy controls and newly diagnosed relapsing MS patients. Results Overall, tracer uptake in the MS brain was not significantly higher compared to HCs. In the 3 mm perilesional rim of all T1 lesions, tracer binding was higher among relapsing patients compared to progressive patients. Tracer binding was higher in males compared to females. Disease duration correlated with tracer binding in the normal appearing white matter. Age correlated negatively with tracer binding in the perilesional rims. Conclusions Binding estimates obtained with the dual-input model were consistent with the expected distribution of P2X₇Rs in the MS brain. According to our study, [¹¹C]SMW139-binding may capture a glial cell phenotype significant in early development of chronic active lesions in relapsing stages of MS. Only tentative evidence for the applicability of [¹¹C]SMW139 to detect MS-related diffuse smoldering inflammation was obtained.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Chauveau F, Becker G, Boutin H. Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies. Eur J Nucl Med Mol Imaging. Springer Science and Business Media Deutschland GmbH; 2021. pp. 201–20.

2. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain [Internet]. 2000;123:2321–37. https://doi.org/10.1093/brain/123.11.2321.

3. Sucksdorff M, Matilainen M, Tuisku J, Polvinen E, Vuorimaa A, Rokka J et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain [Internet]. 2020;143:3318–30. https://www.ncbi.nlm.nih.gov/pubmed/33006604.

4. Rissanen E, Tuisku J, Vahlberg T, Sucksdorff M, Paavilainen T, Parkkola R et al. Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflamm [Internet]. 2018;5:e443. https://www.ncbi.nlm.nih.gov/pubmed/29520366.

5. Misin O, Matilainen M, Nylund M, Honkonen E, Rissanen E, Sucksdorff M et al. Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis. Neurology - Neuroimmunology Neuroinflammation [Internet]. 2022;9:e1182. http://nn.neurology.org/content/9/4/e1182.abstract.